New entrants to multiple sclerosis market will drive 10% pa growth through 2018 – The Pharma Letter
|
New entrants to multiple sclerosis market will drive 10% pa growth through 2018
The Pharma Letter … reformulations of platform injectables and three highly efficacious monoclonal antibodies – Genzyme/Bayer’s (BAYN: DE) Lemtrada (alemtuzumab), Roche (ROG: SIX)/Genentech’s ocrelizumab and Biogen Idec/AbbVie’s (NYSE: ABBV) daclizumab. |
